Evidence map›Paper›PMID 36854171›Full record

ArticleBiochemistry2023

Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk.

Yagmur Kan, YiTing Paung, Yunyoung Kim, Markus A Seeliger, W Todd Miller

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yagmur KanDepartment of Physiology and Biophysics, School of Medicine, Stony Brook University, Stony Brook, New York 11794-8661, United States.ORCID 0000-0002-7127-1356
YiTing PaungDepartment of Pharmacology, School of Medicine, Stony Brook University, Stony Brook, New York 11794-8661, United States.
Yunyoung KimDepartment of Physiology and Biophysics, School of Medicine, Stony Brook University, Stony Brook, New York 11794-8661, United States.ORCID 0000-0002-6592-9545
Markus A SeeligerDepartment of Pharmacology, School of Medicine, Stony Brook University, Stony Brook, New York 11794-8661, United States.ORCID 0000-0003-0990-1756
W Todd MillerDepartment of Physiology and Biophysics, School of Medicine, Stony Brook University, Stony Brook, New York 11794-8661, United States.ORCID 0000-0002-6566-0064
Stony Brook University · USNorthport VA Medical Center · US

Funding

Dynamics of Ligand Binding and Protein Kinase Regulation_RenewalR35GM119437 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Markus A Seeliger · 2016 to 2026
$6.5M
Nonreceptor tyrosine kinases in Systemic Lupus ErythematosusR01AI164424 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI MILLER, W TODD · 2021 to 2025
$1.6M
Robotic assay platformS10OD028478 · OD · STATE UNIVERSITY NEW YORK STONY BROOK · PI SEELIGER, MARKUS A · 2020 to 2020
$173k
Structural and Biochemical Studies of the Insulin and IGF ReceptorsI01BX002292 · VA · NORTHPORT VA MEDICAL CENTER · PI MILLER, W TODD · 2015 to 2022
–
BLRD VA I01 BX002292NIAID NIH HHS R01 AI164424NIGMS NIH HHS R35 GM119437NIH HHS S10 OD028478
6 · The paper itself

Abstract

Tyrosine kinases (TKs) play essential roles in signaling processes that regulate cell survival, migration, and proliferation. Dysregulation of tyrosine kinases underlies many disorders, including cancer, cardiovascular and developmental diseases, as well as pathologies of the immune system. Ack1 and Brk are nonreceptor tyrosine kinases (NRTKs) best known for their roles in cancer. Here, we have biochemically characterized novel Ack1 and Brk mutations identified in patients with systemic lupus erythematosus (SLE). These mutations are the first SLE-linked polymorphisms found among NRTKs. We show that two of the mutants are catalytically inactive, while the other three have reduced activity. To understand the structural changes associated with the loss-of-function phenotype, we solved the crystal structure of one of the Ack1 kinase mutants, K161Q. Furthermore, two of the mutated residues (Ack1 A156 and K161) critical for catalytic activity are highly conserved among other TKs, and their substitution in other members of the kinase family could have implications in cancer. In contrast to canonical gain-of-function mutations in TKs observed in many cancers, we report loss-of-function mutations in Ack1 and Brk, highlighting the complexity of TK involvement in human diseases.

Indexed as

NeoplasmsHumansMutationNeoplasm ProteinsPhosphorylationProtein-Tyrosine KinasesTyrosineNeoplasm ProteinsProtein-Tyrosine KinasesPTK6 protein, humanTNK2 protein, humanTyrosine

Identifiers

PMID36854171
PMCPMC10052838
OpenAlexW4322623433

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.